Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
Research output: Contribution to journal › Journal article › Research › peer-review
MiR34A, B and C have been implicated in lymphomagenesis, but information on their role in normal CD19+ B-cells (PBL-B) and de novo diffuse large B-cell lymphoma (DLBCL) is limited. We show that in normal and activated B-cells miR34A-5p plays a dominant role compared to other miR34 family members. Only miR34A-5p is expressed in PBL-B, and significantly induced in activated B-cells and reactive lymph nodes. In PBL-B, the MIR34A and MIR34B/C promoters are unmethylated, but the latter shows enrichment for the H3K4me3/H3K27me3 silencing mark. Nine de novo DLBCL cases (n=150) carry both TP53 mutation and MIR34A methylation ("double hit") and these patients have an exceedingly poor prognosis with a median survival of 9.4 months (P<0.0001), while neither TP53 mutation, MIR34A or MIR34B/C promoter methylation alone ("single hit") influence on survival. The TP53/MIR34A "double-hit" is an independent negative prognostic factor for survival (P=0.0002). In 2 DLBCL-cell lines with both TP53 mutation and promoter methylation of MIR34A, miR34A-5p is upregulated by 5-aza-2'deoxycytidine. Thus, the TP53/MIR34A "double hit" characterizes a very aggressive subgroup of DLBCL, which may be treatable with epigenetic therapy prior to or in combination with conventional immunochemotherapy.
Original language | English |
---|---|
Journal | OncoTarget |
Volume | 5 |
Issue number | 7 |
Pages (from-to) | 1912-25 |
Number of pages | 14 |
ISSN | 1949-2553 |
Publication status | Published - 15 Apr 2014 |
- Aged, Antigens, CD19, B-Lymphocytes, Cell Line, Tumor, Codon, Nonsense, Female, Humans, Lymph Nodes, Lymphoma, Large B-Cell, Diffuse, Male, Methylation, MicroRNAs, Middle Aged, Mutation, Missense, Prognosis, Promoter Regions, Genetic, Survival Rate, Tumor Suppressor Protein p53
Research areas
ID: 138549705